Shire To Set Out AstraZeneca PLC (AZN)-Style Defense Against AbbVie (ABBV)'s $46 Billion Bid
6/23/2014 6:24:28 AM
(Reuters) - Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.
Flemming Ornskov, Shire’s chief executive, will update investors on prospects for key medicines on Monday afternoon, mirroring the approach of disclosing long-range internal forecasts used by fellow London-listed drugmaker AstraZeneca in its successful defence against Pfizer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by